– OMRON reinforces its involvement with AliveCor with E-series investment and strengthens the alliance between the companies for the remote management of cardiovascular conditions
KYOTO, Japan, Dec.4, 2020 / PRNewswire / – OMRON Healthcare Co., Ltd. announced on November 24 the additional investment in AliveCor by its parent company, OMRON Corporation, as part of the Series E financing of 65 million dollars to the leader in AI-based personal electrocardiogram (ECG) technology. OMRON led this investment round, reinforcing the cross-company collaboration that began in 2017. The companies continue to build their global alliance to accelerate the development of solutions for cardiovascular disease management and remote patient monitoring using ECG technology.
“OMRON is committed to developing life-saving cardiovascular health technologies in pursuit of our Go To Zero vision to eliminate heart attacks and strokes. It is an ambitious goal, and as we said when we evolved our vision, we cannot do it alone. we are looking for like-minded partners like AliveCor to advance our initiatives and work together to save lives, “said Isao Ogino , President and CEO of OMRON Healthcare.
“More than 1 billion adults are hypertensive worldwide (* 1), and their risk of stroke is almost five times higher (* 2) if they also have Afib (atrial fibrillation). Hypertension is also a prominent health condition that increases the risk of complications with COVID-19 (* 3) The ability to control blood pressure and heart rate at home is essential for the early detection, treatment and management of these cardiovascular health conditions.
“Our alliance with AliveCor will help enhance our current technology portfolio and provide hypertensive patients and healthcare professionals with life-saving data, a complete picture of patients’ cardiovascular health that can be achieved with personal remote control technology used at home. We continue to explore and develop new technologies that improve the accessibility of home monitoring to help people manage their condition, and will engage partners like AliveCor to ensure this technology is the best on the market, accelerating our remote patient monitoring business. to reach our goal, Reach Zero, “said Ogino.
OMRON’s expanded investment in AliveCor builds on the current collaboration of the companies. OMRON expanded its blood pressure monitoring portfolio with the launch of “Complete” (TM) the first ECG-capable blood pressure monitor in a single device and the first FDA-cleared technology developed in collaboration with AliveCor in 2019. Currently available in the United States at OmronHealthcare.com and participating retailers, expanded distribution of Complete (TM) is expected in other regions of the world during the company’s fourth quarter.
Notes:
(* 1) World Health Organization: Hypertension ( https://www.who.int/news-room/fact-sheets/detail/hypertension )
(* 2) American Heart Association: High Blood Pressure, AFib and Your Risk of Stroke
(* 3) CDC: People with Certain Medical Conditions ( https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html )
About OMRON Healthcare
Committed to helping people live fuller and more active lives, OMRON Healthcare is a global leader in the field of innovative and clinically proven medical equipment for healthcare management and therapy. Throughout its history, OMRON has strived to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in more than 110 countries. . OMRON offers the world’s number one blood pressure monitoring and the company’s additional core categories are respiratory care, pain management and wellness products. The company also develops a remote patient monitoring service in the field of cardiovascular condition management.
SOURCE OMRON Healthcare Co., Ltd.
